Abstract
Tissue microarrays (TMAs) are produced by taking small punches from a series of paraffin-embedded (donor) tissue blocks and transferring these tissue cores into a positionally encoded array in a recipient paraffin block. Though TMAs are not used for clinical diagnosis, they have several advantages over using conventional whole histological sections for research. Tissue from multiple patients or blocks can be examined on the same slide, and only a very small amount of reagent is required to stain or label an entire array. Multiple sections (100–300) can be cut from a single array block, allowing for hundreds of analyses per microarray. These advantages allow the use of TMAs in high-throughput procedures, such as screening antibodies for diagnostics and validating prognostic markers that are impractical using conventional whole tissue sections. TMAs can be used for immunohistochemistry, immunofluorescence, in situ hybridization, and conventional histochemical staining. Finally, several tissue cores may be taken without consuming the tissue block, allowing the donor block to be returned to its archive for any additional studies.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsSpringer Nature is developing a new tool to find and evaluate Protocols. Learn more
References
Wan, W. H., Fortuna, M. B., and Furmanski, P. (1987) A rapid and efficient method for testing immunohistochemical reactivity of monoclonal antibodies against multiple tissue samples simultaneously. J Immunol Methods 103, 121–9.
Kononen, J., Bubendorf, L., Kallioniemi, A., Barlund, M., Schraml, P., Leighton, S., et al. (1998) Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med. 4, 844–7.
Camp, R. L., Charette, L. A., and Rimm, D. L. (2000) Validation of tissue microarray technology in breast carcinoma. Lab Invest. 80, 1943–9.
Cryan, J., O’Grady, A., Allen, D., and Kay, E. (2009) Tissue microarray technology in the routine assessment of HER2 status in invasive breast cancer. Histopathology 54, 901.
Cunningham, R. E., Abbondanzo, S. L., Chu, W. S., Emory, T. S., Sobin, L. H., and O’Leary, T. J. (2001) Apoptosis, bcl-2 expression, and p53 expression in gastrointestinal stromal/smooth muscle tumors. Appl Immunohistochem Mol Morphol. 9, 19–23.
Dhanasekaran, S. M., Barrette, T. R., Ghosh, D., Shah, R., Varambally, S., Kurachi, K., et al. (2001) Delineation of prognostic biomarkers in prostate cancer. Nature 412, 822–6.
Schlomm, T., Iwers, L., Kirstein, P., Jessen, B., Kollermann, J., Minner, S., et al. (2008) Clinical significance of p53 alterations in surgically treated prostate cancers. Mod Pathol. 21, 1371–8.
Fernandes, A. P., Capitanio, A., Selenius, M., Brodin, O., Rundlof, A. K., and Bjornstedt, M. (2009) Expression profiles of thioredoxin family proteins in human lung cancer tissue: correlation with proliferation and differentiation. Histopathology 55, 313–20.
Eguíluz, C., Viguera, E., Millán, L., and Pérez, J. (2006) Multitissue array review: a chronological description of tissue array techniques, applications and procedures. Pathol Res Pract. 202, 561–8.
Carlson, R. W., Moench, S. J., Hammond, M. E., Perez, E. A., Burstein, H. J., Allred, D. C., et al. (2006) HER2 testing in breast cancer: NCCN Task Force report and recommendations. J Natl Compr Canc Netw. 4 Suppl 3, S1–22.
Dandachi, N., Dietze, O., and Hauser-Kronberger, C. (2002) Chromogenic in situ hybridization: a novel approach to a practical and sensitive method for the detection of HER2 oncogene in archival human breast carcinoma. Lab Invest. 82, 1007–14.
Graham, A. D., Faratian, D., Rae, F., and Thomas, J. S. (2008) Tissue microarray technology in the routine assessment of HER-2 status in invasive breast cancer: a prospective study of the use of immunohistochemistry and fluorescence in situ hybridization. Histopathology 52, 847–55.
Faratian, D., Graham, A., Rae, F., and Thomas, J. (2009) Rapid screening of tissue microarrays for Her-2 fluorescence in situ hybridization testing is an accurate, efficient and economic method of providing an entirely in situ hybridization-based Her-2 testing service. Histopathology 54, 428–32.
Camp, R. L., Chung, G. G., and Rimm, D. L. (2002) Automated subcellular localization and quantification of protein expression in tissue microarrays. Nat Med. 8, 1323–7.
Liu, C. L., Prapong, W., Natkunam, Y., Alizadeh, A., Montgomery, K., Gilks, C. B., et al. (2002) Software tools for high-throughput analysis and archiving of immunohistochemistry staining data obtained with tissue microarrays. Am J Pathol. 161, 1557–65.
Allen, T. C. (1992) Hematoxylin and Eosin. In E. B. Prophet, B. Mills, J. B. Arrington, and L. H. Sobin, ed. AIFP Laboratory Methods in Histotechnology, Armed Forces Institute of Pathology, American Registry of Pathology, Washington, DC, 53–58.
Sauter, G., Simon, R., and Hillan, K. (2003) Tissue microarrays in drug discovery. Nat Rev Drug Discov. 2, 962–72.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2011 Springer Science+Business Media, LLC
About this protocol
Cite this protocol
Fowler, C.B., Man, YG., Zhang, S., O’Leary, T.J., Mason, J.T., Cunningham, R.E. (2011). Tissue Microarrays: Construction and Uses. In: Al-Mulla, F. (eds) Formalin-Fixed Paraffin-Embedded Tissues. Methods in Molecular Biology, vol 724. Humana Press. https://doi.org/10.1007/978-1-61779-055-3_2
Download citation
DOI: https://doi.org/10.1007/978-1-61779-055-3_2
Published:
Publisher Name: Humana Press
Print ISBN: 978-1-61779-054-6
Online ISBN: 978-1-61779-055-3
eBook Packages: Springer Protocols